Day: March 2, 2020

SELSKABSMEDDELELSENr. 54/2020Tvis, 2. marts 2020Ledende medarbejderes transaktioner – CEO køber aktier i TCM Group A/SI henhold til artikel 19 i Markedsmisbrugsforordningen skal TCM Group A/S (“Selskabet”) hermed meddele, at Selskabet har modtaget information om at CEO Torben Paulin har købt aktier i Selskabet for DKK ca. 0,5 mio.Se venligst vedhæftede fil for detaljer.For yderligere information kontakt venligst:CEO Torben Paulin, TCM Group A/S, på tlf. +45 97 43 52 00Om TCM GroupTCM Group er Skandinaviens tredjestørste producent af køkkener og badeværelses- og opbevaringsmøbler. Produkterne er dansk design, produceres i Danmark og er rodfæstet i en stolt tradition for kvalitet og solidt håndværk. TCM Group fører en multibrand-strategi, hvor Svane Køkkenet er det primære brand, mens de øvrige brands er Tvis Køkkener, Nettoline...

Todos evaluating applying its proprietary FTIR platform towards the novel coronavirusSeeking appropriate partners to get access to patient samples to train its AI platformREHOVOT, Israel and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced the publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled “Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis”. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples...

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) — Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has paid off all of its outstanding convertible notes totaling $1.52 million. The notes were paid from the proceeds of a term loan and a direct equity investment by an institutional healthcare investor.“Eliminating these convertible notes represents a significant milestone for Conversion Labs, as now for the first time in two years we are not encumbered by structured financing,” commented company CEO and chairman, Justin Schreiber. “Since the notes were not converted into shares under the original terms, we were also able to avoid substantial dilution to our shareholders.”“Given our outlook for strong growth this year and the rapidly improving fundamentals of the business,” continued Schreiber,...

MASMOVIL Group acquires the virtual mobile operator “Lycamobile España”With this new acquisition, MASMOVIL Group reinforces its position in the prepaid segment, after the integration of Llamaya and Lebara.This operation will generate important synergies that will result in an incremental EBITDA of €75M per year.After the incorporation of this operator, the Group will reach 10.4 million customers in Spain and revenues of €1,800M.Madrid, March 2nd, 2020.– MASMOVIL Group has signed an agreement for the acquisition of the virtual mobile operator “Lycamobile España”, which will allow it to strengthen its position in the prepaid segment, in which it already has an important presence after the purchase of Llamaya and Lebara, and to continue leading the growth of the telecommunications market in Spain.MASMOVIL will pay cash...

TORONTO, March 02, 2020 (GLOBE NEWSWIRE) — Magna Terra Minerals Inc. (the “Company” or “Magna Terra”) (TSX-V: MTT) is pleased to announce the results of its Annual and Special Meeting (the “Meeting”) of Shareholders (the “Shareholders”) held on February 27, 2020. At the Meeting, the Company obtained its standard annual approvals, as well as a number of special items including, notably, a share consolidation on the basis of one (1) new share of Magna Terra for every seven (7) common shares of Magna Terra presently issued and outstanding (the “Share Consolidation”) and the acquisition by Magna Terra (the “Acquisition”) of all of the issued and outstanding common shares of 2647102 Ontario Inc. (“ExploreCo”) from Anaconda Mining Inc. (“Anaconda”) (see news releases dated October 15 and December 3, 2019).As previously disclosed by the...

VANCOUVER, British Columbia, March 02, 2020 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that a significant technological development has been achieved with its FAIMS- (field asymmetric waveform ion mobility spectrometry) marijuana breathalyzer prototype. Cannabix scientists have been characterizing the device for several months to increase resolving power and sensitivity. The Company is pleased to report that the Beta 3.1 FAIMS device has achieved ion-resolving levels that enable the isolation of ∆9-tetrahydrocannabinol (“THC”) in human breath and suppress background compounds effectively. With human subject breath testing performed up to 90 minutes after smoking marijuana and nicotine...

Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in First Half of 2020   Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis and Anticipate Additional Clinical Data and Regulatory Update During 2020Phase 1 Trial of Company’s Third Wholly-Owned Program, ANB030, an anti-PD-1 Agonist Antibody, Anticipated in First Half of 2020 Following IND Submission in Q4 2019GlaxoSmithKline (GSK) Announced BLA Submission of Dostarlimab, a PD-1 Antagonist Antibody Partnered With AnaptysBio, in Endometrial CancerSAN DIEGO, March 02, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates...

BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolismInvestigational new drug (IND)-enabling studies are underway for BOXR1030 with plans to submit an application to the FDA in late 2020Unum concludes its Phase 1 ACTR707 programs and reduces workforce to focus solely on BOXR1030CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unum’s BOXR1030 expresses a glypican-3 (GPC3) targeted CAR and incorporates the novel transgene glutamic-oxaloacetic...

RENO, Nev., March 02, 2020 (GLOBE NEWSWIRE) — Nevada Exploration Inc. (“NGE” or the “Company”) (TSX-V: NGE; OTCQB: NVDEF) is pleased to provide an update regarding its ongoing reverse-circulation (“RC”) drilling program at its South Grass Valley Carlin-type gold project (the “Project”).  Since beginning the program in January 2020, the Company has completed the first of two planned drilling cycles at three of its targets, for a total of approximately 3,600 meters, for which the Company has now received and begun to review assay results for approximately the first 2,400 metres.The Company is pleased to share that the drilling is proceeding on schedule, and that early results from the first three targets are providing additional confidence in the target concepts, described in detail in the Company’s November 15, 2019, news release...

Company to exhibit leading tech solutions from Artificial Intelligence and Augmented Reality to Population Health Analytics and Disease Surveillance PlatformsFLORHAM PARK, N.J., March 02, 2020 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a business process services and solutions company, today announced it will showcase a range of healthcare technology solutions at the 2020 Health Information and Management Systems Society (HIMSS) Global Conference & Exhibition.Conduent provides technology innovations such as artificial intelligence, augmented reality and advanced data analytics to improve financial and clinical outcomes, drive evidence-based programs, and gain key insights into the everyday health of communities. Conduent is moving healthcare data forward with tools that touch two-thirds of all insured patients...